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Aims to evaluate a mHealth intervention to increase medication adherence among 2 
Iranian coronary heart disease patients. 3 
Design Quantitative-dominant mixed-methods study 4 
Data Source Iranian coronary heart disease patients’ responses and most recent 5 
clinical documents as well as responses from Iranian cardiac nurses who 6 
participated in this study. 7 
Methods The study was conducted between September 2015 and April 2016 8 
drawing upon the Medical Research Council’s Framework. Phase one comprised of 9 
a patients’ survey and focus groups with cardiac nurses. The automated short 10 
message service reminder was piloted in phase two. We recruited 78 patients and 11 
randomised to receive either 12-week daily reminders or usual care. The primary 12 
outcome was the effect on medication adherence; secondary outcomes were self-13 
efficacy, ejection fraction, functional capacity, readmission rate and quality of life.  14 
Results Feasibility was evidenced by high ownership of mobile phones and high 15 
interest in receiving reminders. Participants in the intervention group showed 16 
significantly higher medication adherence compared to the control group.  17 
Conclusion The mHealth intervention was well accepted and feasible with early 18 
evidence of effectiveness that needs to be confirmed in a fully powered future 19 




• Poor medication adherence has been identified as a barrier to effective 24 
treatment of coronary heart disease. 25 
• Acceptability and feasibility of a theory-based mHealth intervention to improve 26 




• The mHealth intervention was well-accepted and feasible by Iranian coronary 31 
heart disease patients. 32 
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• The mHealth intervention has the potential to increase cardiovascular 1 
medication adherence; a definitive Randomised Control Trial is required to 2 
confirm the effectiveness. 3 
 4 
Impact? 5 
• Healthcare providers’ perceptions and patients’ preferences need to be 6 
understood when designing interventions. 7 
• The findings can inform the translation and scale-up of text-messaging to 8 
improve medication taking and reduce evidence practice gaps. 9 




Coronary Heart Disease; Secondary Prevention; Medication Adherence; mHealth; 2 
Text Messaging; Nurses; Iran. 3 
  4 
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1. INTRODUCTION 1 
Cardiovascular Disease (CVD) is the main reason for mortality worldwide, 2 
accounting for more than 17 million deaths each year (World Health Organisation, 3 
2019). In particular, mortality rates caused by CVD are increasing in low- and 4 
middle-income countries (World Health Organisation, 2019). Reducing the 5 
prevalence, morbidity and mortality of CVD, as the leading cause of the wider burden 6 
of non-communicable disease, is a major world health priority (World Health 7 
Organisation, 2019). In Iran, Coronary Heart Disease (CHD) - the most important 8 
type of CVD - accounts for nearly 50% of all deaths per year. Approximately 20% of 9 
Iranian adults aged 30 years and over in Tehran, the capital city, have symptoms or 10 
signs of CHD (Hadaegh, Harati, Ghanbarian, & Azizi, 2009). According to a 10-year 11 
population-based cohort study conducted in Iran, the crude CHD incidence rate in 12 
men was about twice that in women (11.9 vs. 6.5 per 1000 person-years) (Khalili et 13 
al., 2014). Given the high prevalence of and a predicted large rise in CHD over the 14 
coming decades, the Ministry of Health and Education of Iran has given priority to 15 
research exploring strategies to reduce cardiovascular mortality by 25% in the next 16 
10 years (Mansoori et al., 2018). 17 
1.1 Background 18 
CHD patients could benefit from treatment to reduce the risk of recurrent 19 
cardiovascular events and mortality; this is known as secondary prevention that 20 
includes Cardiac Rehabilitation (CR), lifestyle changes and pharmacological 21 
treatment (Anderson et al., 2016) Research has shown that consistent use of 22 
medications and participating in CR can improve risk factors and decrease mortality 23 
and hospital readmission (Anderson et al., 2016; Kabboul et al., 2018). Despite the 24 
importance of secondary prevention, Medication Adherence (MA) is suboptimal 25 
among survivors of cardiovascular events; only a range from 13-60% of patients are 26 
fully adherent to anti-platelet, statins, Beta Blockers and the combination of all three 27 
(Garavalia, Garavalia, Spertus, & Decker, 2009; Kyanko, Franklin, & Angell, 2013; 28 
Rodriguez et al., 2013). According to a systematic review of 76 studies conducted in 29 
developing countries including Iran, pooled cardiovascular MA was found to be 30 
unsatisfying (only 57.5%) (Bowry, Shrank, Lee, Stedman, & Choudhry, 2011).  31 
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Poor adherence to medications can be attributed to both intentional (i.e. patient 1 
decides not to follow the treatment) and/or non-intentional (i.e. due to uncontrolled 2 
barriers such as forgetfulness) reasons(Brown et al., 2016). Almost half of the 3 
medication non-adherence is unintentional or due to forgetfulness, complexity of the 4 
treatment regimen, problems of accessibility, cost and competing life demands 5 
(Brown et al., 2016; Gadkari & McHorney, 2012). 6 
There is growing evidence that mHealth interventions are an effective and 7 
acceptable means of improving both intentional and non-intentional adherence 8 
(Hamine, Gerth-Guyette, Faulx, Green, & Ginsburg, 2015; Thakkar et al., 2016). 9 
Mobile phones can deliver interventions via Short Messaging Service (SMS), Smart 10 
phone applications (apps), video messaging, “push” notifications, or via mobile 11 
websites (Kay, Santos, & Takane, 2011). In a recent systematic review of ten studies 12 
of varying designs, 607 patients from five countries were included (Coorey, Neubeck, 13 
Mulley, & Redfern, 2018). Interventions targeted hypertension, heart failure, stroke 14 
and CR populations. According to the authors, MA, rehospitalisation rate and quality 15 
of life were among the factors that were enhanced among mHealth users. The 16 
International Telecommunication Union (2018), reported that there were over 87 17 
million mobile phone subscriptions (108.2 per 100 inhabitants) in Iran.  Iranian main 18 
operators communicated more than 40 million SMS each day (Goodarzi, 19 
Ebrahimzadeh, Rabi, Saedipoor, & Jafarabadi, 2012), allowing extensive reach, 20 
utilisation and potential effectiveness of mHealth solutions. To date and our 21 
knowledge, there have been limited studies on the use of mobile phone to improve 22 
MA exclusively for patients with CHD in the setting of CR in Iran.  23 
2. THE STUDY 24 
2.1 Aim 25 
This study aimed to refine and pilot a pre-developed theory-based mHealth 26 
intervention (BLINDED FOR PEER REVIEW) using the Medical Research Council 27 
(MRC) framework  (2018) to improve cardiovascular MA in Iranian adult, male and 28 
female CR outpatients. Specifically, the focus of this study was on the preclinical, 29 





2.2 Design 1 
In accordance with the MRC framework (2018), the multi-stage mixed-methods study 2 
consisted of the first two consecutive phases of development and feasibility of the 3 
intervention in preparation for a full Randomised Controlled Trial (RCT) (Registration 4 
number: ISRCTN10549665). A text-messaging mHealth intervention had been 5 
developed and piloted previously among ACS patients in Malaysia that showed 6 
significant improvements in MA and heart functional status (BLINDED FOR PEER 7 
REVIEW). This time we tested the same intervention for Iranian CHD patients after 8 
undertaking the stages mapped in the MRC framework to ensure the intervention 9 
would be appropriate to the Iranian context. In the first phase, the theoretical basis of 10 
the intervention was refined; in the modelling phase, exploring Iranian nurses’ and 11 
patients’ views allowed an understanding of required modifications to the 12 
intervention. In the second phase, the feasibility of the intervention was tested. 13 
2.2.1 Phase 1: Intervention (re)Modelling  14 
The theoretical basis of the intervention  15 
We identified and reviewed the relevant theoretical literature, Behaviour Change 16 
Techniques (BCTs) and published evidence base concerning cardiovascular 17 
medication non-adherence. The electronic databases CINAHL (Cumulative Index of 18 
Nursing and Allied Health Literature), Cochrane, Campbell Collaboration, Medline, 19 
Embase, GlobalHealth and PsycINFO to June 2017 were searched using the 20 
following keywords: Cardiovascular diseases/ or heart diseases/ or coronary disease 21 
AND text messaging/ or reminder systems/ or telephone or mobile applications AND 22 
patient compliance/ or MA. The research team identified key findings regarding 23 
mHealth interventions and information deemed suitable to the study setting. 24 
Iterative decisions about search strategy, data extraction and analysis were 25 
discussed in meetings attended by all authors and documented in a study log. Based 26 
on the study focus, the following were set as the inclusion criteria: 27 
-Review or trial mHealth as the main study focus;  28 
-Study utilised mHealth by adults (>18 years) of both gender;  29 
-Published in English language;  30 
Duplicates were removed and articles were excluded if they exhibited one or more of 31 
the following characteristics: 32 
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-The patient was not the study target population (i.e., provider-focused);  1 
-Described a study protocol;  2 
-Involved children and/or people younger than 18 as the target population;  3 
-Used mHealth for acute conditions;  4 
-Used mHealth for assessment, monitoring or measurement;  5 
-Proposed or developed a model or device. 6 
Publications were initially screened for potential inclusion based on the review of title 7 
and abstract by two independent reviewers (BLINDED FOR PEER REVIEW). 8 
Information including objectives, types of mHealth intervention used, setting, study 9 
sample characteristics, outcomes measured, and results reported were extracted 10 
using Microsoft Excel. Usability, feasibility, and acceptability of the applied mHealth 11 
intervention, the theoretical basis and the effect on patient’s outcome (ie. 12 
cardiovascular medication adherence), and any disease-specific clinical outcomes of 13 
the intervention were reviewed. A descriptive review of the studies was performed 14 
and the findings from these research studies summarised, with emphasis on results 15 
reported in trials. Methodological quality was assessed for all full text manuscripts 16 
included in the review. Selected studies were evaluated for their quality using the 17 
Consolidated Standards of Reporting Trials (CONSORT) guidelines for Randomised 18 
Controlled Trials. Any disagreement in interpretation of data and inclusion of studies 19 
between reviewers was resolved by consensus (BLINDED FOR PEER REVIEW).  20 
Patients’ Perception Survey  21 
A self-completion survey conducted among a convenience sample of male and 22 
female CHD (i.e. Myocardial Infarction, angina or revascularisation) patients, aged 23 
18 and over presented at CR clinic in a hospital affiliated to Tehran University of 24 
Medical Sciences (TUMS). Specifically, the survey aimed at identifying:  25 
- the pattern of ownership, utilisation of mobile phones in Iranian CHD patients 26 
(Objective 1); and 27 
- a preferable design for the study intervention based on CHD patients’ 28 
opinions in Iran (Objective 2). 29 
Given that the CR clinic at the study setting had on average 120 admissions per 30 
month for a 24-session exercise programme, then the required sample size was 31 
n=92 with a 95% confidence level, 5% margin of error. Estimating a 70% 32 
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participation rate, 132 eligible CHD patients attending the CR program were asked to 1 
participate over a period of three weeks in September 2015. Of 132 subjects, 123 2 
(93.18%) consented and agreed to complete the questionnaire. All patients 3 
completed sociodemographic information along with the survey questionnaire, self-4 
reported MA and Health-Related Quality of Life (HRQoL) during a face-to-face visit.  5 
Survey Instruments 6 
Electronic Supplementary Material adapted for use from a similar study (Shet et al., 7 
2010) and consisting of 21 items that covered two main domains of enquiry (1) what 8 
is the pattern of ownership and use of mobile phones among CHD patients and; (2) 9 
what might a patient-preferred design for a mobile phone-based intervention to 10 
influence MA look like was utilised.  11 
The Persian-version of the Morisky Self-Reported MA Scale (MMAS-8) was used 12 
after receiving a signed license contract and copyright agreement from the owner. It 13 
is one of the most reliable and widely used scales to determine adherence to 14 
cardiovascular medications. The internal consistency of the MMAS-8 (Cronbach’s 15 
alpha reliability) is 0.83 with good concurrent and predictive validity. This measure 16 
has been also found to positively correlate with pharmacy fills rates (≥75%; r=0.46; 17 
P<0.001) (Morisky, Ang, Krousel‐Wood, & Ward, 2008). The instrument measures 18 
non-adherence to medications for reasons such as forgetfulness, carelessness, 19 
feeling better, or feeling worse (AlGhurair, Hughes, Simpson, & Guirguis, 2012). 20 
HRQoL was evaluated using the validated Persian translation of the Short Form 21 
Health Survey Version 2.0 (SF-12v2). The SF-12v2 is a multi-purpose Short Form 22 
(SF) generic measure of health status that uses a Likert scale format with high 23 
internal consistency, test-retest reliability, construct validity, and criterion validity 24 
(Fleishman, Selim, & Kazis, 2010; Ware et al., 2009). The reliability of the Iranian 25 
version of SF-12v2 for both physical and mental summary measures exceeded the 26 
0.70 level for Cronbach’s alpha indicating satisfactory results (0.87 and 0.82, 27 
respectively) (Montazeri et al., 2011). We used the standard four-week recall period 28 
version in this study. 29 
Focus Groups  30 
Principal Nurse Supervisors/ Matrons in three hospitals affiliated to TUMS were 31 
gatekeepers of the study. They were asked to verbally invite cardiac nurses from CR 32 
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clinics, provide a brief explanation of the study and arrange a date and venue for the 1 
Focus Group Discussions (FGDs). A purposive sample of 23 male and female nurse 2 
staff with at least six months clinical experience were recruited. The FGDs were 3 
conducted and facilitated by (BLINDED FOR PEER REVIEW) on three different days 4 
in November 2015, as part of her PhD studies (which contained qualitative methods 5 
training), mentored by (BLINDED FOR PEER REVIEW), a professor in nursing and 6 
an experienced qualitative researcher. Before the start of the FGDs, (BLINDED FOR 7 
PEER REVIEW) explained the study and the ground rules and importance of 8 
maintaining confidentiality. Then she asked all participants to sign the consent forms. 9 
The FGDs were conducted in the native language of participants, which was typically 10 
Farsi. An interview guide was developed to structure FGDs. Interview questions 11 
were pilot tested with colleagues at TUMS to assess timing and ensure validity. All 12 
responses were open-ended and the discussions were flexible allowing pursuit of 13 
issues raised by the participants that were not in the original FGDs’ protocol. FGDs 14 
specific objectives were to explore: 15 
- Iranian cardiac nurses’ perspectives about the potential effect of a mHealth 16 
intervention among Iranian CHD patients (Objective 3); and 17 
- Potential barriers and facilitators to implementation of the mHealth 18 
intervention through which such interventions may affect cardiovascular MA in the 19 
Iranian context (Objective 4). 20 
Specifically, participants were asked to reflect on (1) their experience with applying 21 
mHealth (2) positive and negative aspects of mHealth (3) challenges of using 22 
mHealth for patients and healthcare providers (4) strategies for best implementing a 23 
mHealth-based intervention to improve cardiovascular MA. All FGDs were audio-24 
recorded with permission from participants and transcribed verbatim after each 25 
session. The average FGD time was fifty minutes. As a validity check, the researcher 26 
asked participants to verify a verbal summary of the key points (Krueger, 2014). 27 
A thematic coding and categorising were used to interpret the data adapted from 28 
approaches to qualitative content analysis discussed by Graneheim and Lundman 29 
(2004). Following steps have been taken: 30 
The transcript was read and brief notes were taken in the margin when interesting or 31 
relevant information was found. After that, the notes made in the margins were 32 
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reviewed and the different types of information were listed. The next step was to 1 
read the list and categorise each item in order to establish a framework of thematic 2 
ideas. It was then identified whether or not the categories could be linked in any way 3 
and they were listed as major or minor themes. At this stage, the various major and 4 
minor categories were compared and contrasted. Finally, all of the categories were 5 
reviewed and it was ascertained whether some categories can be merged or if some 6 
need to then be sub-categorised. All original transcripts were reviewed and all steps 7 
were taken several times to ensure that all the information that needs to be 8 
categorised has been so.  9 
(BLINDED FOR PEER REVIEW) identified themes that emerged from the data. Data 10 
coding was discussed with (BLINDED FOR PEER REVIEW) and (BLINDED FOR 11 
PEER REVIEW), allowing comparison of data interpretation and subsequent coding 12 
refinement. The results were compared and discussed with other authors to reach 13 
agreement.  14 
2.2.2 Phase 2: Feasibility Study 15 
The second phase was conducted between February and April 2016 and included a 16 
12-week feasibility RCT (pre-test, post-test parallel group design) to: 17 
- evaluate the effect of a 12-week mHealth intervention on the primary 18 
outcome: MA of Iranian male and female CHD patients participating in CR 19 
(Objective 5); 20 
- evaluate the effect of a 12-week mHealth intervention on the secondary 21 
outcomes: MA Self-Efficacy (MASE); cardiac Ejection Fraction (EF); cardiac 22 
Functional Capacity (FC); CHD-related readmission/mortality rate and HR-23 
QOL of Iranian male and female CHD patients participating in CR (Objective 24 
6); 25 
- explore the association between socio-demographic factors of the subjects 26 
and MA in both intervention and control groups (Objective 7); 27 
- explore the perception of participants in the intervention group towards the 28 
received mHealth intervention at the end of the study (Objective 8); and 29 
- identify the recruitment and retention rate and inform the sample size required 30 




Sample and Setting 1 
According to Lancaster et al. (2004) for sample size estimation in a feasibility study, 2 
a general rule of thumb is to take 30 patients or greater to estimate a parameter. The 3 
gatekeepers provided a brief explanation of the study to the CHD patients who were 4 
newly admitted to the CR clinic of the same hospital in which the survey and one of 5 
the FGDs were conducted. (BLINDED FOR PEER REVIEW) recruited the patients 6 
(n=78) who agreed to take part in the study and gained their written consent.  7 
Random Allocation 8 
Block randomisation was used with a block size of four. The blocks were chosen 9 
using the random number list generated in Microsoft Excel. Allocation was concealed 10 
using a sealed non-transparent envelope. (BLINDED FOR PEER REVIEW) 11 
generated the random allocation sequence, enrolled participants at the CR clinic, 12 
and assigned participants to interventions. 13 
Control 14 
The control group were not exposed to the study intervention. For the purposes of 15 
this study, usual care was defined as the CR care that was currently provided for 16 
CHD patients 4 to 6 weeks after discharge from hospitals in Iran that involved 24-17 
sessions of supervised exercise training in combination with educational and 18 
psychological support.  19 
Intervention 20 
The intervention group received automated timely medication reminders for 12 21 
weeks based on a predefined template every morning (This pattern was defined 22 
according to the phase I study findings). The 12 weeks of the intervention was 23 
selected as it takes approximately 10 weeks (based on daily repetition) for 24 
participants to adopt new behaviours (eg. medication taking) (Gardner, Lally, & 25 
Wardle, 2012). 26 
A detailed description of the study intervention is presented elsewhere (BLINDED 27 
FOR PEER REVIEW). In short, the software consisted of various parts that were 28 
responsible for gathering and managing the information related to the patients and 29 
their medications, storing data, scheduling, sending text messages and recording 30 
12 
 
delivery reports automatically. Table 1 presents some examples of the text 1 
messages based on the principles of the study theoretical frameworks. 2 
Blinding 3 
Due to the nature of the intervention, it was impossible to blind either the participants 4 
or the researcher to the study group assignment.  5 
Data Collection  6 
Demographic information were collected at baseline. All participants were assessed 7 
face-to-face by (BLINDED FOR PEER REVIEW) in the study site two times: at 8 
baseline (pre-test: T1) and at the endpoint of the study (post-test, after 12 weeks: 9 
T2). At each point in time, all study outcomes were recorded. At the endpoint of the 10 
study, patients who received the intervention were asked to complete a survey on 11 
their satisfaction with the intervention. Feasibility were assessed by records of 12 
recrutiment and participation, reasons for drop-out, and web-analytics to determine 13 
text messages’ delivery.  14 
Measurment Instruments 15 
The primary outcome of interest was the proportion of participants adhering to a 16 
complete cardiac medication regimen at 12 weeks measured using the MMAS-8. 17 
Secondary outcomes were: 18 
- MASE using the 26-item and patient-derived scale (Ogedegbe, Mancuso, 19 
Allegrante, & Charlson, 2003);  20 
- FC using the New York Heart Association (NYHA) classification, LVEF (based 21 
on the exercise test and echocardiography reports by cardiologists who were 22 
unaware of the study group assignment); 23 
- CHD-related readmission/mortality rate (based on the most recent patients’ 24 
documents)  25 
- HRQoL (using two SF-12v2 questionnaires, one pre-test, one post-test 26 
completed by all participants); and  27 
- patients’ perception about the applied intervention using a self-administered 28 





Ethical considerations 1 
Ethical approval obtained from the Research Ethics Committee of the University of 2 
Edinburgh and the Hospitals in which the study took place (Ethics Approval Code: 3 
NURS006 and 92-04-28-28802-145738, respectively).  4 
Data Analysis  5 
 All data were analysed using the computer program Statistical Packages for Social 6 
Sciences (SPSS) version 21. The significance level in this study was α=0.05. The 7 
primary outcome from the MMAS-8 provided categorical data including high 8 
adherence (score of 8), medium adherence (score of 6 to <8) and low adherence 9 
(scores of <6). All secondary outcomes results were provided in categorical data 10 
including FC (Class I: no symptoms, II: mild symptoms, III: marked limitation and IV: 11 
severe limitations), as well as death and hospital readmission rates except the 12 
scores of perceived MASE, EF, and HRQoL. Exploratory statistical analysis was 13 
performed to generate preliminary data and assess within and between-group 14 
differences in primary and secondary outcomes. All statistical tests upon which each 15 
p-value is based have been provided in a footnote to Table 4. Statistical tests were 16 
chosen based on the type of variable (e.g. categorical or continuous) and on whether 17 
the comparison groups were paired or independent. In particular, for the primary 18 
outcome analysis, a Chi-squared test was performed. The outcome of patients’ MA 19 
level (low, medium and high) was cross-tabulated against the study groups 20 
(intervention and control). Since two categories had low number of counts (2 and 3), 21 
we confirmed the primary outcome result by merging the medium and low adherence 22 
categories into a single category called non-adherence, and then applying a Fisher’s 23 
Exact test.  The Relative Risk (RR) with 95% confidence interval was also calculated 24 
based on the risk of non-adherence (“low/medium” adherence) at 12 weeks. The 25 
absolute difference in the percentages of patients with non-adherence at 12 weeks 26 
was also calculated (with 95% CI calculated using the exact method in Altman et al. 27 
2013).  28 
The Multiple Logistic Regression was used to assess any association between 29 
socio-demographic variables (ie. age, sex, education, marital status, employment, 30 
living arrangement, monthly income, family size, diagnosis, diagnosis time, co-31 




There were crucial steps undertaken to ensure the scientific rigour of this study: 2 
(1) the controlled study design with participants randomly allocated to both study 3 
groups;  4 
(2) carefully re-designed and tailored the mHealth intervention to the Iranian context 5 
through undertaking the stages mapped in the MRC framework and understanding 6 
nurses’ perceptions and CHD patients’ preferences; 7 
(3) applying a reliable and validated quantitative measures for primary and 8 
secondary outcomes assessment at baseline and endpoint of the study. 9 
(4) issues of trustworthiness for qualitative phase of the study were carefully followed 10 
by criteria mentioned by Graneheim and Lundman (2004). To achieve credibility, the 11 
participants were selected to have different years of experience, age, and education 12 
level. To address dependability and transferability, the authors provided a clear 13 
description of the context, participants, data collection and process of analysis and 14 
findings followed by some suggestions on how our findings may be transferred to 15 
other contexts. 16 
3. RESULTS 17 
3.1 Phase 1 – Intervention (re)Modelling 18 
3.1.1 The theoretical basis of the intervention  19 
The theoretical basis of the study intervention was based on the principles of self-20 
efficacy within the Social Cognitive Theory (SCT) (Bandura, 2012). Bandura’s SCT is 21 
one of the most relevant theoretical perspectives used in MA reasoning. SCT was 22 
chosen because it concerns perceived self-efficacy and individual goals that 23 
influence the attainment of a new behaviour (eg. taking medications) or the changing 24 
of an existing behaviour (eg. medication non-adherence) over time (Bandura, 2012). 25 
The intervention also benefited from the application of the principles of the WHO 26 
Adherence Model (2003) in which both intra- and interpersonal factors have been 27 
identified as important dimensions that influence MA. According to this model, the 28 
mHealth intervention was designed to improve cardiovascular MA through 29 
addressing the most common barriers to adherence such as patient-related factors 30 
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(eg. forgetfulness and low self-efficacy in taking medications) and healthcare 1 
system-related factors (eg. lack of patient-provider interaction).  2 
The Dixon and Johnston’s Health Behaviour Change Competency Framework 3 
(HBCC) maps each BCT to one or more of three identified routes to behaviour 4 
change, namely: Motivation development to promote skills that help that motivation 5 
to be transformed into Action; and Prompted or cued routes to behaviour (MAP) 6 
(Dixon & Johnston, 2010). The mHealth intervention targeted the third route of the 7 
MAP (i.e. the prompted or cued route) that supports behaviour (i.e. medication 8 
taking) without the need for the constant cognitive attempt required by the other 9 
routes. 10 
3.1.2 Patients’ Perception Survey  11 
The results of the Iranian CHD patients’ survey confirmed the acceptability of using 12 
mHealth  interventions using text messaging to improve MA for this group of 13 
patients. Mobile phone ownership (n=118/123) and the use of text messages 14 
(n=84/123) were relatively high among the respondents of the survey. This finding 15 
indicated that using automated medication reminders delivered by text messaging 16 
might be the most acceptable mHealth intervention in this particular context. Table 2 17 
summarises the remodelling of the intervention based on the findings from both 18 
patients’ survey and nurses’ FGDs following the stages of the MRC framework. 19 
3.1.3 Qualitative Focus Groups  20 
The mean and Standard Deviation (SD) of nurse participants’ age was 36.64 (6.69) 21 
years, predominantly female (19/23, 82.6%), with an average of 12.06 (SD: 6.51) 22 
years’ work experience.  23 
The data from the FGDs confirmed that Iranian cardiac nurses perceived the 24 
mHealth intervention useful for patients who are at risk of medication non-adherence 25 
mostly due to unintentional reasons (e.g. forgetfulness and carelessness) during the 26 
early phase of discharge from hospital. These illustrative quotes support this 27 
assertion: 28 
“It can really work especially for those patients who are forgetful. Some of them 29 
are so busy; but this intervention sends them reminders so that they’ll 30 
remember…now, it’s time for taking medications” (Participant 10, FG 2). 31 
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“The most high risk time is when patients discharge from the hospital. I 1 
mean...when they are at home and they may forget when and how to take their 2 
drugs’’ (Participant 11, FG 2). 3 
Post-discharge follow-up and interaction between patients and healthcare providers 4 
play an important role in the statements expressed by all the FGDs; for example, one 5 
of the more experienced nurses identified that there is no interaction and follow-up 6 
with patients after hospital discharge:  7 
 “Unfortunately, most of our patients are missed after going home and are no 8 
longer in contact with us. That is because our hospitals are inefficient regarding 9 
patients’ post-discharge follow-up and I can say this kind of intervention is absolutely 10 
one of the essentials” (Participant 3, FG 1). 11 
During the nurses’ discussions, a key issue identified was the lack of electronic 12 
health system to provide a connection between hospital and home. The example 13 
below demonstrates that patient-provider connection after inpatient stay can be 14 
established through a remote follow-up using mHealth interventions. 15 
 “There is no interconnected electronic health system or mHealth in our 16 
hospitals. How we can provide follow-up for our discharged patients? You 17 
know…just a few of them may call me if they have questions about their health care 18 
needs and medications. Patients really need this kind of intervention as a means of 19 
follow-up and support from their healthcare providers.” (Participant 9, FG 2). 20 
The nurses also expressed their opinions and recommendations about the 21 
refinement of the study mHealth intervention. The majority of participants suggested 22 
surveying patients and conducting a pilot study to have a better understanding of 23 
feasibility and acceptability of the intervention. They also provided suggestions about 24 
following-up with patients using other mediums along with text messages as well as 25 
pragmatic considerations in developing text message reminders (e.g. less frequent 26 
text messages to prevent patients’ dependency and fatigue over time). More 27 
information can be found in Table 2. 28 
3.2 Phase 2: Feasibility Study 29 
The final mHealth intervention was piloted after refinement as shown in Table 2. 30 
During the recruitment period (February 2016), of 98 CR patients admitted to the 31 
outpatient CR clinic, 78 (76.4%) eligible patients consented to participate in the study 32 
and were randomly assigned to control (n=39) and intervention groups (n=39). 33 
Figure 1 presents the flow diagram of the study based on the CONSORT guideline 34 
(Schultz, 2010). 35 
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Characteristics of all 78 participants are shown in Table 3. All variables were similar 1 
between study groups. 2 
According to the findings from the second phase, the mHealth intervention improved 3 
the primary outcome of the study with a highly significant difference in self-reported 4 
MA levels between the control and intervention groups, χ2 (2) = 23.4; P<0.001. The 5 
RR indicated that it was 2.19 times more likely for the control group to be less 6 
adherent to their medications than the intervention group (RR = 2.19; 95% CI 1.5 - 7 
3.19). The absolute difference between the proportions of non-adherence was 8 
estimated to be 51% (95% CI 35% to 64%). 9 
Among secondary outcomes, the mHealth intervention was significantly associated 10 
with improved MASE scores (U=505; P=0.035) and cardiac FC (χ2 (1) =9.7, 11 
P=0.002) compared with control group.  12 
All secondary outcomes except FC improved significantly in the intervention group at 13 
the end of the study. However, these outcomes showed significant negative changes 14 
in the control group over time. Table 4 illustrates the baseline and follow-up data 15 
obtained from Phase 2 of the study. The study of the association between 16 
participants’ characteristics and MA indicated that socio-demographic data had no 17 
statistically significant relationship with MA. 18 
Findings to Inform Future Definitive Large-scale RCT 19 
In this study, the results showed the majority of the participants (n=28/39, 71.8%) in 20 
the intervention group who received SMS reminders to take their cardiovascular 21 
medications perceived the mHealth intervention positively. The recruitment approach 22 
via CR clinic seemed to work well and indicated feasibility of recruitment. No 23 
financial incentives were offered to the patients. The overal attrition rate was only 24 
3.8% (n=3/78) with the reason for loss to follow-up readmission for surgery. No 25 
harms, unintended consequences or effects were reported.The results of the feasibility 26 
trial helped to inform the sample size needed for a future definitive RCT. A sample 27 
size of 130 patients per group (260 in total) is required to have 90% power to detect 28 
a realistic true difference of 20% or greater for the between-group percentage of 29 
patients with high adherence to their medication in a future study, assuming a (two-30 




4. DISCUSSION 1 
The results showed positive feedback for the acceptability and feasibility of mHealth 2 
intervention to improve cardiocascular MA in an Iranian CR setting. Exploratory 3 
analysis also revealed a significant improvement in the primary and secondary 4 
outcomes of the study. The findings of patients’ perception survey indicated that 5 
there is a high ownership of mobile phones and utilisation of SMS among Iranian 6 
CHD patients and the mHealth intervention perceived helpful by this group of 7 
patients in taking cardiovascular medications. The survey results also confirmed the 8 
importance of obtaining patients’ preferences (shared decision making) about the 9 
timing, frequency and content of text message intervention before they were 10 
implemented. This is consistent with the findings from a systematic review which 11 
identified that mHealth interventions must be flexible as well as culturally and socially 12 
appropriate to the wishes and needs of the patients (Gandapur et al., 2016).  13 
In addition to the patients’ survey results, the intervention was informed by qualitative 14 
findings in which cardiac nurse professionals expressed potential effects of the 15 
mHealth interventions, its associated challenges in the context of Iran and pragmatic 16 
suggestions to enhance the intervention design. This study revealed that Iranian 17 
cardiac nurses were open to the introduction of the mHealth intervention to improve 18 
cardiovascular MA and provided suggestions for optimising the design and 19 
evaluation of the study intervention. In fact, nurses believed that the use of mHealth 20 
intervention would be necessary as it has the potential to improve medication taking 21 
and patients’ link to healthcare providers after discharge. The results are in line with 22 
the findings of a previous study, in which Iranian healthcare professionals have 23 
emphasised the necessity of applying eHealth (i.e. an overarching term that includes 24 
mHealth and teleHealth) in practice (Ayatollahi, Sarabi, & Langarizadeh, 2015).  25 
During the second phase the remodelled intervention was piloted among Iranian 26 
CHD patients to evaluate the acceptability and feasibility in practice. It also provided 27 
the opportunity to determine sample size, the potential effect (effect size), 28 
recruitment and attrition rate. Patients in this study had inadequate MA before the 29 
intervention. The mHealth intervention used in this study improved all primary and 30 
secondary outcomes at the end of the study. These findings are in line with the work 31 
of other researchers that examined the effect of SMS reminders on MA in a variety of 32 
19 
 
medical conditions including asthma (Strandbygaard, Thomsen, & Backer, 2010), 1 
cardiovascular (Fang & Li, 2016; Pfaeffli Dale et al., 2015), diabetic , stroke (Arora, 2 
Peters, Burner, Lam, & Menchine, 2014; Kamal et al., 2015) and hypertensive 3 
patients (Bobrow et al., 2016). 4 
4.1 Implications 5 
Nonadherence to cardiac medications may result in increased morbidity and 6 
mortality, thus mHealth interventions may enhance adherence and health outcomes. 7 
This study has established feasibility and high satisfaction with a text messaging 8 
intervention among patients with CHD. Text message reminders improved 9 
adherence in cardiovascular medications, which are critical in preventing progression 10 
of the negative outcomes, and the disease-related complications during the 11 
vulnerable time following a cardiac event. 12 
In developing countries including Iran, the health care resources are concentrated in 13 
urban areas and health system performance is constrained by limited infrastructure, 14 
inequality and shortages of healthcare providers (Chavehpour, Rashidian, 15 
Woldemichael, & Takian, 2019; Seddighi & Mousavi, 2019). However, according to 16 
the present study findings, automated text-messaging as a type of mHealth 17 
intervention has the potential to help by removing physical barriers to care and 18 
service delivery and by improving poor patient-provider communication. This could 19 
also help nurses, as the primary providers of healthcare, to achieve the Sustainable 20 
Development Goals (SDGs) and support dimensions of Universal Health Coverage 21 
(UHC). Unlike complicated interventions and time-consuming face-to-face 22 
approaches, SMS reminders are transmitted automatically to patients beyond a 23 
specific location with limited efforts from health care professionals. Although there is 24 
a potential for low-cost scalability and reproducibility of mHealth, evidence for the 25 
effectiveness of mHealth use in improving health-related quality measures, such as 26 
disability-adjusted life-years remains limited, especially for the developing world. 27 
Finally, economic outcomes are considerable. The effectiveness of mHealth 28 
interventions to improve secondary prevention of cardiovascular disease has 29 
important implications from financial perspective, as well. This is particularly of 30 
importance when considering that medication nonadherence was found to be the 31 
leading cause of CHD-related rehospitalisations in Iran, increasing the economic 32 
20 
 
burden of this disease (Heydarpour, Saeidi, Ezzati, Soroush, & Komasi, 2015). 1 
Improved cardiovascular health outcomes and eliminated health care expenses for 2 
both patients and health system, could justify mHealth solutions. Further research is 3 
needed to economically evaluate the mHealth interventions, their costs, and their 4 
intended clinical outcomes and potential adverse effects. 5 
4.2 Limitations 6 
There are some limitations to the present study that should also be noted. Because 7 
the sample size was small and only included CHD patients who presented at an 8 
outpatient CR clinic, they might not represent the wider Iranian CHD population. In 9 
addition, the intervention was refined and tailored to the Iranian settings which may 10 
limit the generalisability of the study findings to wider country settings. However, 11 
linking the components of the intervention to the theory or conceptual framework 12 
may be an effective way to address the generalisability issue of the study findings 13 
and provide a sound theoretical basis for further studies in other country settings.  14 
Another study limitation is the patients’ self-completion bias, although the self-report 15 
questionnaire is simple, cost-efficient and the most common method of data 16 
collection (Basu, Garg, Sharma, & Singh, 2019; Jimmy & Jose, 2011). It may be 17 
affected by recall bias and socially desirable responding (Basu et al., 2019; Berben 18 
et al., 2011); however, a comparison of other studies demonstrated that there was 19 
an association between a patient’s self-report of medication intake and blood drug 20 
levels (Grover, Oberoi, Rehan, Gupta, & Yadav, 2019; Ho, Bryson, & Rumsfeld, 21 
2009). According to the literature, there is no “gold standard” to measure MA 22 
behaviour (Basu et al., 2019; Jimmy & Jose, 2011). Direct methods such as the 23 
detection of a metabolite or marker in patients’ blood are often impractical, costly and 24 
invasive (Stewart, Mc Namara, & George, 2014). Moreover, to the researcher's 25 
knowledge, electronic monitoring devices for medication taking were not available in 26 
Iran during the study time. There was no electronic pharmacy claim data in this 27 
country to monitor the prescription refill or measuring adherence using Medication 28 
Possession Ratio (MPR) and Proportion of Days Covered (PDC). Pill counts may not 29 
be a reliable method because patients can appear adherent by changing 30 
medications between bottles or throwing them out before a follow-up visit (Basu et 31 
al., 2019; Jimmy & Jose, 2011). To address the issue of subjectivity of self-reporting, 32 
21 
 
we used results of electrocardiograms, stress tests and echocardiograms of the 1 
patients to assess the NYHA, FC and LVEF. 2 
Our results may also have been subject to the bias inherent in the application of the 3 
randomisation, intervention and data collection by the same researcher. Careful 4 
efforts were made to prevent any influence on the data collection and analysis during 5 
or after the trial. All stages of the study had a clear plan and supervised by two 6 
professors and one doctor in nursing who had expertise both in the field of 7 
quantitative and qualitative research methods. Having several meetings with all 8 
authors and statistician helped to minimise the bias that the pre-assumptions might 9 
cause.  10 
5. CONCLUSIONS 11 
Qualitative and quantitative data collected in this study suggested that the mHealth 12 
intervention had the desired effect on cardiovascular MA among Iranian CHD 13 
patients. The study findings also confirmed that the recruitment and data collection 14 
strategies used were feasible for implementation in a larger RCT. According to the 15 
MRC framework, the next step will be to assess the intervention cost-effectiveness 16 
and to validate the present study results by conducting a definitive RCT. As the 17 
major contribution to global practice, the findings inform the translation and scale-up 18 
of the text-messaging technology to improve CHD patients’ self-efficacy in 19 
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